InMed Pharmaceuticals Inc. INM announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences.
In the peer-reviewed study, researchers analyzed the effects of rare cannabinoids tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”), cannabigerol (“CBG”) and cannabigerolic acid (“CBGA”) on the major endocannabinoid system elements in skin cells.
Using a widely recognized in vitro model of human keratinocytes, researchers studied how these cannabinoids interacted with several receptors including cannabinoid receptors and other endocannabinoid system components.
In summary, each cannabinoid had distinct biological activity via the endocannabinoid system. In particular, THCV was shown to perform as a cannabinoid receptor 1 (“CB1”) antagonist and have a high affinity for the human transient receptor potential vanilloid 1 (“TRPV1”), which is involved in skin sensation, as did CBC albeit to a lesser extent. The results from the study support additional research of these rare cannabinoids for their potential effect on skin conditions.
“This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” stated Dr. Eric Hsu, senior VP, preclinical research and development. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”
InMed’s subsidiary, BayMedica LLC, manufactures commercial-scale, high purity, bioidentical rare cannabinoids for the health and wellness industry. BayMedica launched B2B sales of THCV in June 2020, adding to its portfolio which also includes cannabidivarin (“CBDV”), cannabicitran (“CBT”) and CBC.
Photo by Ryan Lange on Unsplash
Related News
InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!